Skip to main content
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Analysts Are Bullish on Top Healthcare Stocks: Roivant Sciences (ROIV), Boston Scientific (BSX)

Tipranks - Tipranks - Thu Apr 9, 11:16AM CDT

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Roivant Sciences (ROIV) and Boston Scientific (BSX) with bullish sentiments.

Easter Sale - 70% Off TipRanks

Roivant Sciences (ROIV)

TD Cowen analyst Yaron Werber maintained a Buy rating on Roivant Sciences on April 6 and set a price target of $38.00. The company’s shares closed last Wednesday at $28.43.

According to TipRanks.com, Werber is a 5-star analyst with an average return of 23.3% and a 58.8% success rate. Werber covers the Healthcare sector, focusing on stocks such as Ultragenyx Pharmaceutical, Terns Pharmaceuticals, and Ionis Pharmaceuticals. ;'>

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Roivant Sciences with a $33.56 average price target, a 18.0% upside from current levels. In a report issued on April 2, TipRanks – PerPlexity also upgraded the stock to Buy with a $31.00 price target.

See the top stocks recommended by analysts >>

Boston Scientific (BSX)

In a report issued on April 6, Matthew O’Brien from Piper Sandler reiterated a Buy rating on Boston Scientific, with a price target of $105.00. The company’s shares closed last Wednesday at $62.40.

According to TipRanks.com, O’Brien is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of -7.9% and a 35.3% success rate. O’Brien covers the Healthcare sector, focusing on stocks such as Kestra Medical Technologies Ltd., Shoulder Innovations, Inc., and Tandem Diabetes Care. ;'>

Boston Scientific has an analyst consensus of Strong Buy, with a price target consensus of $103.00, a 63.9% upside from current levels. In a report issued on March 30, TipRanks – PerPlexity also upgraded the stock to Buy with a $77.00 price target.

Read More on ROIV:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).